KRYS
Krystal Biotech, Inc. NASDAQ Listed Sep 20, 2017$296.98
Mkt Cap $8.8B
52w Low $122.80
96.7% of range
52w High $303.00
50d MA $262.97
200d MA $219.81
P/E (TTM)
37.6x
EV/EBITDA
39.6x
P/B
6.3x
Debt/Equity
0.0x
ROE
16.8%
P/FCF
37.8x
RSI (14)
—
ATR (14)
—
Beta
0.54
50d MA
$262.97
200d MA
$219.81
Avg Volume
283.4K
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
2100 Wharton Street · Pittsburgh, PA 15203 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 4, 2026 | TNS | 1.45 | 1.83 | +26.2% | 286.95 | +1.5% | -0.8% | +0.7% | +3.4% | — | — | — |
| Feb 17, 2026 | TNS | 1.62 | 1.70 | +4.9% | 287.84 | -0.4% | -1.6% | -8.7% | -9.0% | -4.6% | -7.3% | — |
| Nov 3, 2025 | TNS | 1.12 | 2.66 | +137.5% | 197.85 | +0.0% | +2.7% | +1.0% | +1.1% | +0.0% | +0.8% | — |
| Aug 4, 2025 | TNS | 1.08 | 1.29 | +19.4% | 134.94 | +0.4% | +1.8% | +0.8% | +0.9% | +2.8% | +1.9% | — |
| May 6, 2025 | TNS | 1.38 | 1.20 | -13.0% | 139.47 | +0.8% | -1.9% | -1.6% | -5.2% | -0.0% | -3.5% | — |
| Feb 19, 2025 | TNS | 1.29 | 1.52 | +17.8% | 176.17 | +4.7% | +3.7% | +6.6% | +6.1% | +2.8% | +0.1% | — |
| Nov 4, 2024 | TNS | 0.90 | 0.91 | +1.1% | 170.85 | +1.0% | +2.1% | +7.2% | +8.5% | +16.8% | +14.6% | — |
| Aug 5, 2024 | TNS | 0.50 | 0.86 | +72.0% | 180.71 | +0.9% | -1.2% | -3.3% | -0.2% | +0.8% | +2.0% | — |
| May 6, 2024 | TNS | 0.15 | 0.03 | -80.0% | 156.94 | -0.2% | +3.1% | +0.5% | +1.1% | -1.4% | -1.4% | — |
| Feb 26, 2024 | TNS | -0.38 | 0.30 | +178.9% | 157.00 | +1.9% | +8.4% | +3.9% | +1.6% | +6.9% | +1.9% | — |
| Nov 6, 2023 | TNS | -1.10 | -0.67 | +39.1% | 103.77 | +1.0% | +5.1% | -1.5% | -7.5% | -5.0% | -3.9% | — |
| Aug 7, 2023 | TNS | -0.42 | -1.25 | -197.6% | 108.51 | +0.6% | +6.8% | +9.2% | +11.3% | +9.6% | +10.8% | — |
| May 8, 2023 | AMC | -1.41 | -1.76 | -24.8% | 87.65 | -1.0% | +4.8% | +2.8% | +3.0% | +0.6% | +2.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 25 | Guggenheim | Maintains | Buy → Buy | — | $266.90 | $266.90 | +0.0% | +2.1% | +3.5% | +3.3% | -3.0% | -1.2% |
| Feb 18 | Citigroup | Maintains | Buy → Buy | — | $287.84 | $286.67 | -0.4% | -1.6% | -8.7% | -9.0% | -4.6% | -7.3% |
| Feb 18 | Chardan Capital | Maintains | Buy → Buy | — | $287.84 | $286.67 | -0.4% | -1.6% | -8.7% | -9.0% | -4.6% | -7.3% |
| Feb 17 | Jefferies | Maintains | Buy → Buy | — | $276.45 | $289.00 | +4.5% | +4.1% | +2.5% | -5.0% | -5.3% | -0.7% |
| Feb 2 | Goldman Sachs | Maintains | Buy → Buy | — | $279.24 | $276.58 | -1.0% | +1.1% | +0.1% | -3.6% | -4.2% | -2.3% |
| Jan 22 | BofA Securities | Maintains | Buy → Buy | — | $286.00 | $286.20 | +0.1% | +1.1% | -1.6% | -2.5% | -3.0% | -4.6% |
| Jan 12 | Citigroup | Maintains | Buy → Buy | — | $261.41 | $260.64 | -0.3% | +4.1% | +11.7% | +11.6% | +7.9% | +9.0% |
| Jan 9 | TD Cowen | Maintains | Buy → Buy | — | $248.91 | $254.51 | +2.2% | +5.0% | +9.3% | +17.3% | +17.2% | +13.3% |
| Jan 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $248.91 | $254.51 | +2.2% | +5.0% | +9.3% | +17.3% | +17.2% | +13.3% |
| Jan 9 | Citigroup | Maintains | Buy → Buy | — | $248.91 | $254.51 | +2.2% | +5.0% | +9.3% | +17.3% | +17.2% | +13.3% |
| Jan 6 | Citigroup | Upgrade | Neutral → Buy | — | $244.71 | $250.44 | +2.3% | +1.9% | +0.7% | +1.7% | +6.8% | +11.2% |
| Nov 4 | Citigroup | Maintains | Neutral → Neutral | — | $197.85 | $197.94 | +0.0% | +2.7% | +1.0% | +1.1% | +0.0% | +0.8% |
| Nov 4 | Chardan Capital | Maintains | Buy → Buy | — | $197.85 | $197.94 | +0.0% | +2.7% | +1.0% | +1.1% | +0.0% | +0.8% |
| Oct 17 | BofA Securities | Maintains | Buy → Buy | — | $188.33 | $192.91 | +2.4% | +1.0% | +4.1% | +1.3% | -1.0% | -1.0% |
| Sep 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $143.68 | $146.52 | +2.0% | +8.4% | +7.4% | +7.2% | +11.8% | +13.8% |
| Aug 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $145.70 | $146.36 | +0.5% | +3.3% | +0.7% | +0.8% | +1.3% | +3.5% |
| Aug 22 | Chardan Capital | Maintains | Buy → Buy | — | $145.70 | $146.36 | +0.5% | +3.3% | +0.7% | +0.8% | +1.3% | +3.5% |
| Aug 5 | Citigroup | Maintains | Neutral → Neutral | — | $134.94 | $135.51 | +0.4% | +1.8% | +0.8% | +0.9% | +2.8% | +1.9% |
| Aug 5 | Chardan Capital | Maintains | Buy → Buy | — | $134.94 | $135.51 | +0.4% | +1.8% | +0.8% | +0.9% | +2.8% | +1.9% |
| Jul 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $150.00 | $150.44 | +0.3% | -1.6% | +1.9% | +1.4% | +2.1% | +2.6% |
| Jul 25 | Chardan Capital | Maintains | Buy → Buy | — | $150.00 | $150.44 | +0.3% | -1.6% | +1.9% | +1.4% | +2.1% | +2.6% |
| Jul 22 | BofA Securities | Maintains | Buy → Buy | — | $148.09 | $148.51 | +0.3% | +2.6% | +3.5% | +1.3% | -0.3% | +3.3% |
| Jul 10 | Citigroup | Maintains | Neutral → Neutral | — | $148.90 | $148.79 | -0.1% | +0.6% | -0.5% | +1.0% | -0.8% | +0.8% |
| Jun 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $137.92 | $139.05 | +0.8% | +4.2% | +3.3% | +3.4% | +0.7% | -0.3% |
| May 16 | Citigroup | Maintains | Neutral → Neutral | — | $130.33 | $130.15 | -0.1% | +0.2% | +1.5% | +0.9% | -2.8% | -3.9% |
| May 7 | Guggenheim | Maintains | Buy → Buy | — | $139.47 | $140.64 | +0.8% | -1.9% | -1.6% | -5.2% | -0.0% | -3.5% |
| May 7 | Chardan Capital | Maintains | Buy → Buy | — | $139.47 | $140.64 | +0.8% | -1.9% | -1.6% | -5.2% | -0.0% | -3.5% |
| May 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $162.29 | $143.01 | -11.9% | -14.1% | -15.7% | -15.5% | -18.6% | -14.1% |
| Apr 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $169.73 | $168.47 | -0.7% | +0.5% | +0.1% | -2.4% | -2.1% | -4.4% |
| Apr 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $168.06 | $169.49 | +0.9% | +1.0% | +1.5% | +1.1% | -1.4% | -1.1% |
| Feb 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $173.35 | $173.45 | +0.1% | +3.4% | -0.9% | +1.1% | +3.9% | +3.2% |
| Feb 20 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $176.17 | $184.53 | +4.7% | +3.7% | +6.6% | +6.1% | +2.8% | +0.1% |
| Feb 20 | Citigroup | Maintains | Neutral → Neutral | — | $176.17 | $184.53 | +4.7% | +3.7% | +6.6% | +6.1% | +2.8% | +0.1% |
| Feb 20 | Chardan Capital | Maintains | Buy → Buy | — | $176.17 | $184.53 | +4.7% | +3.7% | +6.6% | +6.1% | +2.8% | +0.1% |
| Feb 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $156.69 | $149.25 | -4.7% | +12.4% | +16.5% | +19.9% | +19.3% | +15.6% |
| Dec 18 | Chardan Capital | Maintains | Buy → Buy | — | $169.04 | $176.59 | +4.5% | -7.3% | -4.9% | -2.5% | -4.9% | -6.2% |
| Dec 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $169.04 | $176.59 | +4.5% | -7.3% | -4.9% | -2.5% | -4.9% | -6.2% |
| Dec 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $173.40 | $173.28 | -0.1% | -5.6% | -3.3% | -2.5% | -9.7% | -7.2% |
| Dec 12 | Chardan Capital | Maintains | Buy → Buy | — | $187.12 | $191.16 | +2.2% | -7.3% | -12.5% | -10.4% | -9.7% | -16.3% |
| Dec 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $184.40 | $181.96 | -1.3% | +0.7% | +1.5% | -6.0% | -11.3% | -9.1% |
| Nov 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $170.85 | $172.48 | +1.0% | +2.1% | +7.2% | +8.5% | +16.8% | +14.6% |
| Nov 5 | Citigroup | Maintains | Neutral → Neutral | — | $170.85 | $172.48 | +1.0% | +2.1% | +7.2% | +8.5% | +16.8% | +14.6% |
| Sep 11 | Stifel | Maintains | Buy → Buy | — | $185.00 | $185.34 | +0.2% | +7.5% | +5.8% | +9.0% | +5.0% | +2.3% |
| Aug 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $203.91 | $205.57 | +0.8% | -4.3% | -4.3% | -8.4% | -8.8% | -8.8% |
| Aug 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $198.22 | $199.00 | +0.4% | +2.9% | -1.5% | -1.6% | -5.8% | -6.2% |
| Aug 12 | Evercore ISI | Maintains | Outperform → Outperform | — | $182.17 | $182.37 | +0.1% | +1.2% | +2.9% | +3.4% | +6.5% | +5.6% |
| Aug 6 | Citigroup | Downgrade | Buy → Neutral | — | $180.71 | $182.40 | +0.9% | -1.2% | -3.3% | -0.2% | +0.8% | +2.0% |
| Aug 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $191.94 | $165.00 | -14.0% | -5.9% | -6.9% | -9.0% | -6.0% | -5.1% |
| Aug 5 | Chardan Capital | Maintains | Buy → Buy | — | $191.94 | $165.00 | -14.0% | -5.9% | -6.9% | -9.0% | -6.0% | -5.1% |
| May 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $161.76 | $160.07 | -1.0% | -2.5% | -1.9% | -4.3% | -4.3% | -1.4% |
No insider trades available.
8-K · 2.02
!! High
Krystal Biotech, Inc. -- 8-K 2.02: Earnings Results
Krystal Biotech disclosed Q1 2026 financial results on May 4, 2026, showing its operational performance and financial condition for the quarter ending March 31, 2026.
May 4
8-K
Krystal Biotech, Inc. -- 8-K Filing
Krystal Biotech delivered robust 2025 results with $730.3 million in VYJUVEK revenue while advancing its pipeline through FDA's RMAT designation for KB707 in lung cancer and Fast Track status for KB111 in heart disease.
Feb 17
Data updated apr 25, 2026 6:05pm
· Source: massive.com